Health
Eisai: Canada's Drug Agency Recommendation Denies Canadians Safer Insomnia Treatments
Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, is deeply disappointed by Canada's Drug Agency (CDA-AMC)'s recommendation to not publicly reimburse DAYVIGO (lemborexant) for the treatment of chronic insomnia disorder (CID), characterized by difficulties with sleep onset and/or maintenance occurring at least three nights per week for a minimum of three months. This is the second time CDA-AMC has made this recommendation. In th
About this update from Eisai Co., Ltd.
[{"type":"text","content":"MISSISSAUGA, ON, Jan. 29, 2026 /CNW/ - Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, is deeply disappointed by Canada's Drug Agency (CDA-AMC)'s recommendation to not publicly reimburse DAYVIGO (lemborexant) for the treatment of chronic insomnia disorder (CID), characterized by difficulties with sleep onset and/or maintenance occurring at least three nights per week for a minimum of three months. This is the second time CDA-AMC has made this recommendation. In the most recent submission, Eisai submitted real-world clinical evidence demonstrating the benefit of DAYVIGO for patients and the healthcare system. Additionally, extensive patient and clinician input was provided supporting the benefits of DAYVIGO, representing 90 clinicians and four patient organizations. Despite the new evidence and overwhelming stakeholder support, reimbursement was not recommended by CDA. The implications are significant: lack of public coverage for innovative therapies like DAYVIGO creates inequities and forces patients and clinicians to choose ineffective or harmful alternatives.","length":1156,"tagName":"p"},{"type":"image","alt":"Eisai Logo (CNW Group/Eisai Limited)","displaySize":"","headline":null,"caption":"Eisai Logo (CNW Group/Eisai Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":210,"url":"https://media.zenfs.com/en/cnwgroup.com/f54a85da38992c67abe5b1f0687ec6f2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AC.rNbOTLbC5nH7jYC5DoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM3MDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/f54a85da38992c67abe5b1f0687ec6f2","width":400,"height":210}},"href":"https://mma.prnewswire.com/media/2869418/Eisai_Limited_Eisai__Canada_s_Drug_Agency_Recommendation_Denies.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This recommendation perpetuates a cycle of inadequate care and unmet need for millions of Canadians struggling with insomnia who have to rely on treatments not intended for long-term use. Furthermore, this recommendation perpetuates the use of treatments which contradict Canadian expert consensus recommendations that support the value of DAYVIGO in addressing a critical gap in chronic insomnia care.1 The Canadian consensus indicates that Dual Orexin Recept...